ImmunOs Therapeutics AG

📍 Schlieren, Switzerland🗓 Founded 2014👥 31 employees💰 Last funded Apr 2020
Biotechnology🌐 immunostherapeutics.com
Website LinkedIn
ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).
3
Total investors
1
Early stage
1
Mid stage
1
Late stage
2014
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
3
Investor activity2014–2020 · investors recorded per year
201412019120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ImmunOs Therapeutics AG?
ImmunOs Therapeutics AG has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did ImmunOs Therapeutics AG last raise funding?
The most recent investment in ImmunOs Therapeutics AG recorded on gritt.io was in April 2020.
When was ImmunOs Therapeutics AG founded?
ImmunOs Therapeutics AG was founded in 2014.
What industry is ImmunOs Therapeutics AG in?
ImmunOs Therapeutics AG operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is ImmunOs Therapeutics AG based?
ImmunOs Therapeutics AG is headquartered in Schlieren, Switzerland.